PAB
$15M17mo
Patrys
Biotech · Oncology
Deoxymabs (cell-penetrating antibodies) targeting intracellular DNA damage repair for cancer
Cash data from Dec 2025 4C(5mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.9M
Dec 2025 4C
Runway
17moADEQUATE
Based on Dec 2025 4C
Market Cap
$15M
Burn Rate
$0.3M/qtr
Dec 2025 4C
Shares Outstanding
343M
Pipeline Assets
1
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveCapital Raise19 Apr 2026
$3.2 million Placement to Advance Clinical Trials
$3.2MPlacement·at$0.024·133.0M shares
Lead: Templar Corporate Pty Ltd
3M Price
PAB.ASX$0.043+34.4% 3M
Low $0.025High $0.045
Pipeline Assets (1)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
Capital Raises & Buybacks
12mo dilution 39.5%12mo $53M2 raises
Current shares outstanding: 343M
Placement
2026-06-08placement
$50.0M
2026-04-20placement
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (5)· 2 upcoming · 3 past
Expectedarrow_upwardHigh30 Sept 2026
Expectedarrow_upwardHigh31 Dec 2026
expand_more3 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 5 tracked
Completed catalysts
✓Patrys advances RLS-2202 toward Phase 1 Clinical Trial· readout — subject to clinical uncertainty— No clinical results are available yet as the trial has not commenced. Patrys has appointed CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as CRO to manage the bridging PK, safety and tolerability study in healthy volunteers. Subject to HREC approval, first participant dosing is targeted for Q3 CY2026.
On time
✓Proposed issue of securities - PAB
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.